Gain Therapeutics Reports First Quarter 2023 Financial Resul

Successfully completed GLP toxicology studies for lead program GT-02287 in GBA1 Parkinson’s diseaseCompany is on track to submit application for start of Phase 1 clinical trial of GT-02287 to... | May 12, 2023

Related Keywords

Sweden , Gothenburg , Vastra Gotalands Lan , Australia , Helsinki , Eteläuomen Läi , Finland , Switzerland , Swiss , Matthias Alder , C Evan Ballantyne , Evan Ballantyne , Gain Therapeutics Inc , Company Annual Report On Form , Exchange Commission On , Silverstein Foundation For Parkinson , Human Research Ethics Committee , University Of Helsinki , Institute For Research , European Union Horizon , International Conference On Alzheimer , Nasdaq , Exchange Commission , Michaelj Fox Foundation For Parkinson Research , Swiss Innovation Agency , Gain Therapeutics , Chief Financial Officer , Chief Executive , Cell Based Models , Amyloid Beta , Swiss Accelerator , Newcells Biotech , Months Ended March , Silverstein Foundation , Swiss Accelerator Innovation Project , Private Securities Litigation Reform Act , Annual Report , Media Contact , Nc Stock Exchange , News , Information , Press Release , Uccessfully , Ompleted , Help , Toxicology , Studies , Or , Head , Program , N , Ba1 , Iseasecompany , Us , Track , O , Ubmit , Application , Start , F , Hase , , Linical , Trial , F Ganx Us36269b1052 ,